Skip to main content

Table 2 Association of VEGF-A, VEGF-B, VEGFR2 and VEGFR3 mRNA expression with basic patient and tumor characteristics.

From: The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial

  

VEGF-A mRNA expression

VEGF-B mRNA expression

VEGFR2 mRNA expression

VEGFR3 mRNA expression

  

(Number = 307)

(Number = 304)

(Number = 308)

(Number = 308)

  

Median

Range

P value

Median

Range

P value

Median

Range

P value

Median

Range

P value

Age

<50

34.8

(32.4-38.3)

0.001

35.3

(33.1-37.5)

<0.001

32.1

(29.6-34.4)

0.190

31.9

(27.4-34.2)

0.030

 

≥50

35.3

(28.2-38.3)

 

35.7

(27.5-38.0)

 

32.2

(29.2-34.5)

 

32.1

(29.1-34.4)

 

Treatment group

E-T-CMF

35.0

(33.4-38.3)

0.629

35.5

(27.5-37.4)

0.13

32.1

(29.5-34.5)

0.99

32.0

(27.4-34.0)

0.47

 

E-CMF

35.1

(28.2-38.3)

 

35.5

(32.4-38.0)

 

32.1

(29.2-34.4)

 

32.1

(29.1-34.4)

 

Menopausal status

Premenopausal

34.8

(32.4-38.3)

0.001

35.4

(33.1-37.5)

0.002

32.1

(29.6-34.4)

0.17

31.9

(27.4-34.2)

0.069

 

Postmenopausal

35.3

(28.2-38.3)

 

35.7

(27.5-38.0)

 

32.3

(29.2-34.5)

 

32.1

(29.1-34.4)

 

ER/PgR status

Negative

35.5

(32.4-38.3)

<0.001

35.4

(27.5-38.0)

0.023

32.3

(29.6-34.4)

0.310

32.1

(27.4-34.4)

0.288

 

Positive

34.9

(33.1-38.0)

 

35.6

(33.4-37.6)

 

32.1

(29.2-34.5)

 

32.0

(29.1-34.4)

 

HER2 statusa

Negative

35.0

(28.2-38.2)

0.020

35.5

(32.4-37.5)

0.856

32.0

(29.2-34.5)

0.088

32.0

(29.1-34.4)

0.294

 

Positive

35.4

(33.4-38.3)

 

35.6

(27.5-38.0)

 

32.4

(29.5-34.4)

 

32.4

(27.4-34.4)

 

Positive nodes

0 to 3

35.0

(32.4-38.1)

0.97

35.4

(33.7-37.2)

0.51

32.0

(30.3-34.1)

0.42

31.9

(30.0-34.2)

0.35

 

≥4

35.0

(28.2-38.3)

 

35.6

(27.5-38.0)

 

32.1

(29.2-34.5)

 

32.0

(27.4-34.4)

 

Tumor size

≤2

34.9

(28.2-38.0)

0.13

35.7

(33.4-36.9)

0.140

32.2

(29.6-34.3)

0.44

32.2

(27.4-34.4)

0.43

 

2-5

35.0

(32.4-38.3)

 

35.4

(27.5-38.0)

 

32.0

(29.2-34.5)

 

32.0

(29.1-34.4)

 
 

>5

35.3

(33.1-37.9)

 

35.5

(33.1-37.6)

 

32.2

(29.5-34.0)

 

32.1

(29.4-34.1)

 

Histological grade

I-II

34.9

(28.2-38.0)

0.027

35.6

(33.1-37.6)

0.024

32.2

(29.9-34.4)

0.25

32.1

(29.5-34.4)

0.12

 

III-IV

35.1

(32.4-38.3)

 

35.4

(27.5-38.0)

 

32.0

(29.2-34.5)

 

32.0

(27.4-34.4)

 

Adjuvant HT

No

35.8

(33.1-37.9)

0.003

35.5

(33.8-36.8)

0.59

32.1

(30.1-33.9)

0.85

31.8

(29.9-33.6)

0.62

 

Yes

34.9

(28.2-38.3)

 

35.5

(27.5-38.0)

 

32.1

(29.2-34.5)

 

32.0

(27.4-34.4)

 

Adjuvant RT

No

35.4

(32.4-37.9)

0.17

35.4

(33.4-37.2)

0.72

32.0

(30.1-34.1)

0.52

31.9

(29.4-33.9)

0.48

 

Yes

35.0

(28.2-38.3)

 

35.5

(27.5-38.0)

 

32.1

(29.2-34.5)

 

32.1

(27.4-34.4)

 
  1. Normalized mRNA expression values (40-delta CT) are presented. Comparisons were made using the Mann-Whitney test, except for tumor size where the Kruskall-Wallis test was used. aPositive HER2 status: HER2 3+ by IHC and/or HER2 amplification by FISH. Significant P values are shown in bold. CMF, cyclophosphamide, methotrexate, fluorouracil; CT, cycle threshold; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; HT, hormonal therapy; PgR, progesterone receptor; RT, radiation therapy; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us